CommentarySildenafil: medical advance or media event?
References (12)
- et al.
Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study
J Urol
(1994) Erectile dysfunction: the medicalization of male sexuality
Clin Psychol Rev
(1996)- et al.
Relationship between contraction and relaxation in human and rabbit corpus cavernosum
Urology
(1993) Impotence
JAMA
(1993)- et al.
The social organization of sexuality: sexual practices in the United States
(1994) - et al.
On life satisfaction in male erectile dysfunction
Int J Impot Res
(1997)
Cited by (30)
Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film
2017, Journal of Sexual MedicineCitation Excerpt :PDE5is, including sildenafil, tadalafil, vardenafil, and avanafil, are currently approved for use in ED and each has an individual pharmacokinetic and side effects profile, although no significant differences in efficacy among therapies are evident.1,5–8 Sildenafil, the first approved PDE5i, is a safe and effective oral agent for the treatment of ED and is predominantly metabolized by cytochrome P-450 into an N-desmethyl metabolite (N-desmethyl sildenafil) that accounts for approximately 1 fifth of the drug's activity.9,10 Oral administration of a tablet can lead to 2 types of effects. (
Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: A narrative review and meta-analysis
2014, Journal of Sexual MedicineCitation Excerpt :The combination of PI and PDE5‐Is is a promising strategy for a favorable outcome in ED and can be considered as a first‐choice option for ED patients. This finding is in contrast to the prevailing clinical routine, where PDE5‐Is are prescribed [59] as a single treatment, or are, unfortunately, ordered via the Internet [60] by patients themselves. Therefore, a public health implication would be the importance of increasing public awareness about the promising effects of PI for ED within combined therapy.
Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation With a Film-Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study
2013, Clinical TherapeuticsCitation Excerpt :Sildenafil, the first approved, safe and effective oral agent for the treatment of ED, is a potent and selective inhibitor of cyclic guanosine monophosphate–specific phosphodiesterase type 5. Sildenafil is predominantly metabolized by cytochrome P-450 into an N-desmethyl metabolite (N-desmethyl sildenafil) that accounts for approximately one fifth of the drug's activity.7,8 Since the launch of sildenafil in 1998, it has been approved and used as a film-coated tablet (FCT) formulation.
Toward Personalized Sexual Medicine (Part 2): Testosterone Combined with a PDE5 Inhibitor Increases Sexual Satisfaction in Women with HSDD and FSAD, and a Low Sensitive System for Sexual Cues
2013, Journal of Sexual MedicineCitation Excerpt :In these women, administration of sublingual 0.5 mg testosterone might increase the brain's sensitivity for sexual cues, which might activate excitatory mechanisms in the brain involved in sexual motivation and desire [5-8]. Sufficient sexual stimulation of the brain is necessary for a phosphodiesterase type 5 inhibitor (PDE5i)-mediated increase in the genital sexual response [9,10]. Because central mechanisms (sexual motivation) play a large role in sexual stimulation, PDE5i's will generally have little to no effect when activation of central sexual mechanisms is reduced or absent.
HIV: Associated transmission risks in older adults - An integrative review of the literature
2004, Journal of the Association of Nurses in AIDS CareLong-term efficacy of sildenafil and tachyphylaxis effect
2001, Journal of Urology